IRB approval for trial with US Dept of Veterans Affairs
Filed with ASX · · 2 pages · English
Summary by 6ix AI
TrivarX Limited has received Institutional Review Board approval for a clinical trial with the US Department of Veterans Affairs to screen for major depressive episodes using its technology. The trial aims to assess the accuracy of TrivarX's ECG algorithm compared to traditional methods.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from TrivarX
- TrivarX Receives Firm Commitments to Raise $2.25 million
- Trial with US Department of Veterans Affairs
- Appendix 4D & Half-Year Financial Report to 31 December 2024
- December 2024 Quarterly Activities Report and Appendix 4C
- TrivarX Receives $1.03m R&D Tax Incentive
Later from TrivarX
- March 2025 Quarterly Activities Report and Appendix 4C
- First patient recruited in innovative mental health trial
- June 2025 Quarterly Activities Report and Appendix 4C
- Appendix 4E - Preliminary Final Report
- Trading Halt
Follow TrivarX into a list and get an email when it puts out news.
Follow TrivarX